Pharmadrug, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Kideckel
- Full Time Employees
- 9
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 77 King Street West Toronto ON Canada M5K 1H1
- IPO Date
- Aug 16, 2018
- Website
- pharmadrug.co
- Similar Companies
- Business
- PharmaDrug Inc. is a specialty pharmaceutical company engaged in the research, development, and commercialization of controlled substances and natural medicines, including psychedelics and previously approved drugs. The company's core products and services include the development and clinical advancement of reformulated natural-based medicines targeting oncology and infectious diseases; synthetic formulations of existing drugs tailored to meet emerging drug policy reforms; and the development of cepharanthine, a patented enteric-coated formulation for treating infectious diseases and rare cancers. PharmaDrug operates through subsidiaries such as Sairiyo Therapeutics, which focuses on reformulating natural medicines for clinical trials and regulatory approval, and SecureDose Synthetics, which has recently ceased operations due to strategic shifts. Founded and headquartered in Toronto, Ontario, PharmaDrug primarily serves the biotechnology and pharmaceutical sectors with a focus on therapeutic molecules and medical products derived from natural sources. Its recent strategic initiatives include a definitive agreement to acquire up to a 40% equity interest in Canurta Inc., a biotechnology firm pioneering botanical therapeutics for inflammatory and neurodegenerative diseases, enhancing PharmaDrug’s biotechnology profile and pipeline with innovative drug candidates like CNR-401 targeting Amyotrophic Lateral Sclerosis (ALS). Additionally, PharmaDrug is advancing the clinical development of PD-001, its patented cepharanthine formulation, supported by contracts such as a $3.4 million award from the U.S. Defense Threat Reduction Agency to conduct Phase 1 clinical trials. In 2025, PharmaDrug undertook a comprehensive strategic review process led by independent directors to explore potential asset sales, restructurings, and consolidation opportunities aimed at maximizing shareholder value. This review also led to the discontinuation of SecureDose's operations, aligning the company’s focus solely on clinical and commercial development of therapeutic molecules. PharmaDrug's activities span North America with an emphasis on leveraging its proprietary clinical development platforms and strategic collaborations to enhance its pipeline and expand commercial presence in the natural and controlled substances pharmaceutical space. The company continues to pursue growth through partnerships, biotechnology investments, and innovative therapeutic drug development.
Company News
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
PharmaDrug Announces Debt Restructuring
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
PharmaDrug Announces Issuance of Debenture Units
PharmaDrug Announces Proposed Issuance of Debenture Units
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Announces Director Appointment and Resignation
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman